Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Myasthenia Gravis Companies

Myasthenia gravis (MG) is a chronic, complex, autoimmune disorder that affects the neuromuscular junction and leads to varying degrees of muscle weakness and fatigue. There are several companies involved in research, development, and support related to Myasthenia Gravis.

*Disclaimer: List of key companies in no particular orderLatest Myasthenia gravis Companies Update

September 2023: Recipharm and Ahead Therapeutics formed a partnership to collaboratively develop a novel therapeutic intervention for myasthenia gravis, a rare autoimmune disorder. Ahead Therapeutics is a biotechnology company based in Spain that utilizes its proprietary technology to develop therapeutic interventions for a variety of autoimmune conditions. Recipharm will provide analytical and process development expertise to facilitate toxicological research, as well as Good Laboratory Practice (GLP) manufacturing of lipid nanoparticles for the encapsulation of the active pharmaceutical ingredient, namely an antigen peptide. Recipharm also offers the capacity to expand manufacturing operations to facilitate the future commercialization of the drug. By employing a biomimetic strategy, liposomes are able to induce antigen-specific immunological tolerance, thereby halting the autoimmune response.

September 2023: UCB, a prominent biopharmaceutical company, announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) had granted approval for two of its medications, RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan). These medications have been approved for the treatment of generalized myasthenia gravis (gMG) in adult patients whose response to corticosteroids or other immunosuppressants has been inadequate. Japan has earned the distinction of being the first nation to simultaneously grant approval for rozanolixizumab and lucoplan. This means that for the first time, Japanese physicians and their patients will be able to choose between two novel targeted medications for the treatment of generalized myasthenia gravis (gMG) from a single pharmaceutical company, thereby providing unique options and adaptability. UCB is presented with an opportunity to provide personalized and ground-breaking benefits to adult patients in Japan who are afflicted with generalized myasthenia gravis (gMG) due to the company's prestigious group of Japanese medical and scientific professionals as well as its extensive background in the field of neurology.

List of Myasthenia gravis Key companies in the market

GE Healthcare

Novartis AG

Boston Scientific Corporation

Grifols S.A.

Koninklijke Philips N.V.

Alexion Pharmaceuticals Inc.

Myasthenia Gravis Market Highlights:

Myasthenia Gravis Market Size

Myasthenia Gravis Market Trends

Myasthenia Gravis Market Analysis

Myasthenia Gravis Market Share

Myasthenia Gravis Market Highlights:

Myasthenia Gravis Market Trends

Myasthenia Gravis Market Analysis

Myasthenia Gravis Market Share

Myasthenia Gravis Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.